Investigating new treatments for acute myeloid leukemia using retinoic acid receptors
Official title: Molecular Pharmacology Lab
Funded at Leidos Biomedical Research, INC. · NIH-11219753 · Data updated 2026-11-12
This study is looking at how certain compounds can help improve treatments for acute myeloid leukemia (AML) and similar cancers by boosting the immune system and finding ways to target cancer cells without harming healthy ones, making therapies safer and more effective for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Leidos Biomedical Research, INC. NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | September 28, 2024 |
| Project end | August 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $872,000 |
| NIH project number | 75N91019D00024-0-759102400011-9 |
| Project ID | NIH-11219753 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with acute myeloid leukemia or related aneuploid cancers.
✕Less likely to help
Patients with non-hematological cancers or those who do not have aneuploidy may not benefit from this research.
What this research studies
This research focuses on using retinoic acid receptor (RAR) and retinoid X receptor (RXR) agonists and antagonists to explore important pathways that can help fight acute myeloid leukemia (AML) and related cancers. The team has previously contributed to the development of FDA-approved therapies for acute promyelocytic leukemia (APL) and is now studying how these retinoids can enhance immune-based treatments. They are also investigating a newly discovered pathway that targets cancer cells while protecting normal cells, which could lead to more effective and safer cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies for patients with acute myeloid leukemia and other related cancers.
How similar studies have gone: Previous research has successfully demonstrated the effectiveness of retinoid-based therapies in treating acute promyelocytic leukemia, indicating a promising avenue for similar approaches in AML.
Where this research is happening
-
Leidos Biomedical Research, INC.
Frederick, United States Active
Researchers
- Principal investigator: Briscoe, Lynn — Leidos Biomedical Research, INC.
- Study coordinator: Briscoe, Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.